Issue Date | Title | Author(s) |
2013 | The caregiving perspective in heart failure: a population based study | Davidson, P; Abernethy, A; Newton, P; Clark, K; Currow, D |
2013-03-01 | Chronic refractory dyspnoea: Evidence based management | Wiseman, R; Rowett, D; Allcroft, P; Abernethy, A; Currow, D |
2013-11-01 | Evidence-based intervention for chronic refractory breathlessness: Practical therapies that make a difference | Currow, D; Johnson, M; White, P; Abernethy, A |
2015-09-01 | Indicators of integration of oncology and palliative care programs: An international consensus | Hui, D; Bansal, S; Strasser, F; Morita, T; Caraceni, A; Davis, M; Cherny, N; Kaasa, S; Currow, D; Abernethy, A; Nekolaichuk, C; Bruera, E |
2015-01-01 | Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD) | Ekström, M; Bornefalk-Hermansson, A; Abernethy, A; Currow, D |
2016-09-01 | OR45: Body Composition in Non-Small Cell Lung Cancer (Nsclc) Patients with Cachexia and Improved Anorexia-Cachexia Symptoms: Anamorelin Phase 3 Trials Pooled Analysis | Fearon, K; Currow, D; Temel, J; Giorgino, R; Friend, J; Abernethy, A |
2016-11-25 | Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy | Ekström, M; Ahmadi, Z; Bornefalk-Hermansson, A; Abernethy, A; Currow, D |
2015-09-01 | Results From Phase III Trials of Anamorelin in Advanced Non-Small Cell Lung Cancer Patients with Cachexia: ROMANA 1 and 2 | Abernethy, A; Fearon, K; Friend, J; Yan, Y; Duus, E; Currow, D |
2017-08-01 | ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia | Currow, D; Temel, JS; Abernethy, A; Milanowski, J; Friend, J; Fearon, KC |
2011-08-30 | Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. | Uronis, H; McCrory, DC; Samsa, G; Currow, D; Abernethy, A |